For this session, the first segment will examine market dynamics that companies must navigate to successfully launch products in these regions. Attendees will be equipped with insights on how a knowledgeable manufacturing operating unit and optimized supply chain is vital to ensure acceleration and flawless execution and that leveraging historical data, lessons learned, and technology can enable predictive planning. The second segment will explore the critical link between supply chain security and product quality with a special focus on how risk is factored into best practices for remote GMP auditing and the challenges to overcome. The third segment, FOYA 2023 Pharma 4.0 Awardee, Genentech, invested $240 million in a state-of-the-art biologics facility that integrates advanced technologies to support the clinical supply chain. The presentation focuses on executing the project innovatively, establishing a culture of curiosity and boldness. Topics include leadership, team engagement, qualification approaches, and future operations organization.
By participating in this session, attendees will gain a comprehensive understanding of the key considerations and strategies for introducing new products into emerging markets, gain insights into the risks and vulnerabilities that exist in supply chains and the strategies and technologies that companies can implement to mitigate those risks.

1345 – 1410: New Product Introduction in the Pharmaceutical Landscape by Erica Torres and Lindsey Daniel
1410 – 1430: The Link Between Supply Chain Security and Quality by Jim Fries
1430 – 1450: FOYA Pharma 4.0: Facility of the Future: Design Philosophy and Vision for Genentech’s New Clinical Supply Center by Jeff Davis and Michael Greening
1450 – 1515: Question and Answer/Panel Discussion moderated by Aaron Weinstein